These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 7461567)

  • 1. [Prevention of urinary calculi by means of a benzbromarone-citrate combination].
    Bach D; Hesse A; Strenge A; Vahlensieck W
    Fortschr Med; 1980 Nov; 98(44):1752-5. PubMed ID: 7461567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP
    Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
    Fortschr Med; 1979 May; 97(17):835-6. PubMed ID: 437646
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR; Dreykluft HR; Leonhardt H
    Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of dietary factors on the risk of urinary stone formation.
    Hesse A; Siener R; Heynck H; Jahnen A
    Scanning Microsc; 1993 Sep; 7(3):1119-27; discussion 1127-8. PubMed ID: 8146611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F; Neuwirth R; Berg G
    Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of an allopurinol/benzbromaron preparation on the composition of urine in a circadian course].
    Hesse A; Schneeberger W; Vahlensieck W
    Klin Wochenschr; 1987 Mar; 65(5):218-24. PubMed ID: 3573681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
    Sakhaee K; Poindexter JR; Griffith CS; Pak CY
    J Urol; 2004 Sep; 172(3):958-61. PubMed ID: 15311008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: a study in outpatients.
    Murayama T; Sakai N; Yamada T; Takano T
    Int J Urol; 2001 Oct; 8(10):525-31; discussion 532. PubMed ID: 11737477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of benzbromaron in gout patients with limited kidney function].
    Kuzmits R; Bresnik W; Müller MM
    Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients].
    Matzkies F
    Fortschr Med; 1978 Aug; 96(32):1619-21. PubMed ID: 680625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and tolerance of a new benzbromarone preparation].
    Jelke K; Neubauer M; Krause G; Jüttner A; Angar T; Grosse-Kielisch C; Bach GL
    Med Welt; 1980 May; 31(21):821-2. PubMed ID: 7392938
    [No Abstract]   [Full Text] [Related]  

  • 16. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N; Jansen B; Hesse A
    Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circadian rhythms of lithogenic and inhibitory substances in the urine].
    Ebisuno S; Morimoto S; Yasukawa S; Yoshida T; Fukatani T; Minakata S; Uehara M; Ohkawa T
    Hinyokika Kiyo; 1986 May; 32(5):667-71. PubMed ID: 3751794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Normurat (benzbromaron) in the treatment of gout].
    Bosmanský K; Trnavský K
    Z Rheumatol; 1979; 38(9-10):342-8. PubMed ID: 525067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
    Matzkies F; Berg G; Minzlaff R
    Fortschr Med; 1977 Jul; 95(27):1748-50. PubMed ID: 332605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.